including without limitation Dupixent ® (dupilumab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

The FDA approval is still pending, creating uncertainty around the market acceptance and commercial success of Dupixent for treating bullous pemphigoid, which may affect investor confidence.

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that rocatinlimab improves outcomes in atopic dermatitis, but questions about ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

Dupixent also demonstrated superiority over ... GlobalData is the parent company of Pharmaceutical Technology. Despite the commercial success, tensions between Regeneron and Sanofi have escalated.

After several months, inflammatory disease medication Dupixent has finally reclaimed its spot atop the rankings for over-the-counter (OTC) and Rx brand marketing on TV. The Regeneron and Sanofi brand, ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD <li /> Five times more adults on Dupixent achieved s ...